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Abstract
Purpose: Except for early stages (T1/2 N0), the prognosis for patients with oral cavity cancer (OCC) is known to be
worse than for those with pharyngeal carcinoma. While definitive intensity modulated radiation therapy
(IMRT)-chemotherapy affords loco-regional control rates (LRC) of approximately 80% in advanced pharyngeal
cancer, corresponding rates are reported to be much lower for OCC. The aim of this work was to evaluate loco-
regional disease control and overall survival (OAS) in a relatively large OCC patient cohort treated in the IMRT era.
Methods and materials: Between October 2002 and June 2011, 160 OCC patients were treated with curative
intention IMRT at our department. 122 patients (76%) were referred with primary disease and 38 patients (24%)
with a recurrent OCC at least 3 months after surgery alone. Definitive IMRT was performed in 44/160 patients (28%),
whilst 116 patients underwent previous surgery. Simultaneous systemic therapy was administered in 72%.
Results: Patients with postoperative IMRT (+/−systemic therapy) with R0-1 status (n = 99) reached significantly
higher LRC/OAS rates than patients following IMRT for macroscopic disease (n = 61), with 84%/80% versus 38%/33%
at 3 years, respectively (p< 0.0001). This was found in patients treated for initial, as well as recurrent, disease. Less
than 2% persisting grade 3/4 late effects were observed.
Conclusions: IMRT for R0-1 situations translated into a highly significant superior LRC and OAS compared to the
IMRT cohort treated for macroscopic disease. Treatment was well tolerated.
Keywords: IMRT in oral cavity cancer, Definitive IMRT for oral cavity cancer, Prognostic parameter in oral cavity
cancer, Salvage treatment for recurrent oral cavity cancer, Recurrent oral cavity cancer
Purpose
Except for early stages (T1/2 N0) [1,2], the efficacy of
primary radiation of oral cavity cancer (OCC) is known
to be worse than for pharyngeal carcinoma. Although
definitive intensity modulated radiation therapy (IMRT)-
chemotherapy affords loco-regional control rates (LRC)
of approximately 80% in advanced pharyngeal cancer,
corresponding rates are reported to be much lower for
OCC [3–5].
The impact of IMRT on the survival and local control
has not been, up to now, definitively stated. The aim of
this work was to evaluate the loco-regional disease con-
trol and overall survival in a relatively large OCC patient
cohort treated with IMRT.
Methods and materials
Patients
Between October 2002 and June 2011, 160 OCC patients
were treated with curative intention IMRT at our Depart-
ment of Radiation Oncology, Table 1. 122 patients (76%)
were referred at initial diagnosis, and 38 patients (24%)
presented with a recurrence after surgery only. Definitive
IMRT was performed in 44 patients (28%; mean/median
primary gross tumor volume (GTV) 41 cc/29 cc (range,
0–162); mean/median nodal GTV 8.5 cc/3 cc (0–67);
mean/median total GTV 49 cc/41 cc (9–162)). Details on
the follow up time are listed in Table 1).
Table 2 shows the analyzed population. Seventeen of
116 (15%) postoperative IMRT patients presented with
macroscopic disease at the time of the IMRT planning
computed tomography (CT): in two patients due to in-
complete surgery (R2); in a further 15 operated patients,
rapid macroscopic disease progression developed in the
short interval between operation and beginning of IMRT
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(mean interval of 6.2 weeks, range 4–10). Ten of these
17 patients developed nodal disease only (macroscopic
tumor volume 1–11 cc (mean 5.5 cc)), 2/17 had only
local disease (5 and 10 cc), and 5/17 presented with
loco-regional disease (13–67 cc (mean 35 cc)). Post-
operatively detected macroscopic disease was histologi-
cally confirmed in patients with doubtful new lesions; in
patients with clinical or radiological very obvious and
suspicious lesions (newly developed, large, contrast en-
hancing, central necrosis), radiological as well as clinical
evidence was considered sufficient for diagnosis. In all
17 postoperative patients with macroscopic disease vis-
ible in the IMRT planning CT, the ‘postoperative’ IMRT
dose was increased to 70 Gy, according to the standard
dose for definitive IMRT.
The remaining 99/116 operated patients were on
macroscopic evaluation disease free (resection margin
free or only microscopic involved (R0-1)).
Patients referred for salvage treatment of local and/or
nodal recurrence after surgery alone (n= 38) were separ-
ately analysed and outcomes compared to that in the sub-
group treated for primary disease (n=122).
Table 1 Patient and disease characteristics in oral cavity cancer (OCC, N= 160)
Parameters PATIENTS
Postoperative IMRT Definitive IMRT
N patients 116 44
concomittant systemic therapy 78 (67%) 30 (68%)
Induction chemotherapy 2 (2%) 5 (11%)
Gender, male / female 69% / 31% 57% / 43%
Age, mean / median (range) 59 / 58 (25–90) years 66 / 64 (41–85) years
WHO performance status 0, 1, 2 83%, 13%, 4% 62%, 34%, 4%
Histology: squamous cell carcinoma 114 (98%) 43 (98%)
adenoid cystic carcinoma (ACC) 0 1
Merkel cell carcinoma 2 (2%) 0
Localization: T/FoM 74 (64%) 30 (68%)
mandible/alveolar process/TR 32 (28%) 7 (16%)
buccal mucosa (cheek) 8 (7%) 4 (9%)
others (lip, palate) 2 (2%) 3(7%)
T stage: rT0 9 (8%) 0
rT+ 17 (15%) 10 (23%)
T1 16 (14%) 1 (2%)
T2 35 (30%) 6 (14%)
T3 10 (9%) 6 (14%)
T4 29 (25%) 21 (48%)
N stage: rN0 5 (4%) 2 (5%)
rN+ 15 (13%) 2 (5%)
N0 36 (31%) 12 (27%)
N 1a-2b 44 (38%) 13 (30%)
N2c 10 (9%) 15 (34%)
N3 1 (1%) 0
Stage I 5 (4%) 0
II 10 (9%) 0
III 17 (15%) 1 (2%)
IV 57 (49%) 33 (75%)
nodal or primary recurrence 27 (23%) 10 (23%)
Follow up, mean/median (range) all patients 33 / 18 (2–101) months 20 / 12 (1–87) months
alive patients 35 / 35 (2–101) months 33 / 22 (5–87) months
dead patients 24 / 22 (5–66) months 12 / 8 (3–27) months
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In addition, the potential impact of the site of the
tumor (cancer of the mobile tongue and floor of mouth
versus buccal mucosa versus jaw / alveolar process / ret-
romolar trigone versus others (lip/palate), +/− systemic
therapy, gender, age, and the TN stage were assessed.
Toxicity was assessed based on RTOG/EORTC Radi-
ation Morbidity Score. Both classifications have been
considered; for simplification, grade 3 or 4 late reactions
were termed 'grade 3/4' reactions. Subacute/late mucosal
ulceration grade 3/4 was therefore defined as deep and/
or bleeding ulcer.
Radio-osteonecrosis (RON) was scored according to a
formerly described and used grading system [6]: grade 2
was defined as exposed bone with signs of infection or
sequestration (corresponding to the NCI and EORTC
classification of a grade 2 RON); grade 3 as RON treated
with mandible resection, with satisfactory result; grade 4
as RON with persistent problems despite mandible re-
section; and grade 5 as death due to RON.
During the course of irradiation, all patients were clinic-
ally assessed at regular weekly intervals, and 2 weeks to
2 months after completion of treatment. Four to 6 weeks
after completion of IMRT, all patients were seen regularly
in our joint clinics at the Departments of Cranio-
Maxillofacial Surgery and Head and Neck Surgery. Institu-
tional standards for patient assessment included physical
examination with body weight monitoring approximately
every 2 months in the first year of follow-up, every
3 months in the second to third year and every 6 months
in the fourth to fifth year. In addition, radiological evalua-
tions based on CT, magnetic resonance imaging or posi-
tron emission tomography-CT was performed at 6 to
12 months intervals, or in case of suspicious findings, in
parallel to histological examination.
IMRT: indications, technique and dosage
General indications for postoperative radiation in oper-
ated patients were: locally advanced stages, positive sur-
gical margins, perineural spread and involvement of 2 or
more lymph nodes or extra-capsular extension. Pre-
scribed dose ranged between 60–66 Gy in 2 Gy per frac-
tion. The elective nodal volume was defined depending
on the situation: no elective radiation in pN0-1 with suf-
ficient number of nodes resected form the relevant nodal
levels; contralateral cervical nodal irradiation (54 Gy in
1.64-1.8 Gy per fraction) for large and/or non-lateralized
primaries, or >2 ipsilateral lymph node metastases, or
large nodal metastasis.
Reasons for primary IMRT were patient preference
(4/44) and medical and/or surgical reasons in the
remaining 40 patients.
IMRT was delivered by 6 MV photon beams on a Var-
ian linear accelerator with sliding window technique.
The technical solution of choice was a 5 field arrange-
ment (‘class solution’) for all patients. 70 Gy or 69.6 Gy
in 35 and 33 fractions was administered for definitive
IMRT; one patient received 74 Gy. IMRT treatment was
delivered using a simultaneously integrated boost (SIB)
technique in all patients; details on SIB are reported
elsewhere [7]. The dose in electively irradiated regions
was 54 Gy in 33 fractions (range 50–56).
The high dose planning target volume (PTV1)
included the gross tumor volume (GTV) and a margin
of approximately 1–1.5 cm. Elective irradiation of
lymphatic regions in T3/4 or N+ situations included
level I,II,III and lV bilaterally of the neck and level V on
the ipsilateral side. In patients with N+, the retropharyn-
geal nodes bilaterally were also included. On the unin-
volved side of the neck, the upper field border was at
the lower border of the transverse process of C1.
Patient alignment was checked before each irradiation
by portal imaging; deviations of >3 mm were corrected
before treatment.
Volume delineation, dose calculation and plan
optimization was performed on a Varian Treatment Plan-
ning System (EclipseW, Version 7.3.10, Varian Medical
Systems, Hansen Way, Palo Alto CA, 94304–1129).
Contouring and dose distribution reviews of all cases
have been performed by the first and/or the last author.
Chemotherapy
Simultaneous chemotherapy was administered in 72%
patients. All definitive as well as postoperative irradiated
patients with no specific contra-indications underwent
concomitant cisplatin chemotherapy (40 mg/m2 once
weekly), or cetuximab therapy (standard dosage,
400 mg/m2 loading dose, 250 mg/m2/week afterwards;
also used in operated patients with advanced disease).
Seven patients with very large lesions and questionably
curative options were treated with induction chemother-
apy (taxotere, cisplatin, 5-fluorouracil), aiming to assess
disease response with respect to a subsequent curative
versus palliative treatment approach, or to ‘down stage’
tumor load prior to a surgical option. Concomitant
chemotherapy was given after induction chemotherapy
whenever possible/tolerated.
Table 2 Analyzed population, with focus on the presence
of macroscopic (GTV+) versus microscopic (GTV-) disease
160 OCC patients 116 postoperative
IMRT (72%)
44 definitive
IMRT (28%)
122 primary disease (76%) 81: GTV− 34 (GTV+)
7: GTV+
38 recurrent disease (24%) 18: GTV- 10 (GTV+)
10: GTV+
61 GTV+ (%) 17 44
99 GTV- (%) 99 0
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Statistics
All statistical analyses consisted of comparing groups
according to a time-to-event endpoint (survival analysis),
using Kaplan-Meier curves and log-rank tests implemen-
ted in StatViewW (Version 4.5). P values< 0.05 were
considered as significant.
Results
Fifty-three patients (53/160, 33%) experienced loco-
regional treatment failure +/− distant metastases
(20 patients with local failure only, 4 with nodal failure
only, 7 with distant failure only, 13 with loco-regional
failure, 6 with loco-regional and distant failure, 8 with
local and distant and 3 with nodal and distant failure).
Salvage surgery was performed in 8 of the 53 patients
(15%), and was successful in 2 patients (with nodal dis-
ease only). Distant metastasis free survival was 83%.
Forty-four out of the 53 loco-regional failures (83%)
developed in the first 12 months after completion of
therapy, 21/24 (87%) of distant failures and 45/55 (82%)
of deaths occurred during the first 24 months after
IMRT. 58% of all patients were alive with no evidence of
disease when last seen, 9% were alive with disease, 3%
had inter-currently died with no evidence of disease, and
31% had died from disease.
Impact of macroscopic disease
Postoperative IMRT patients with R0-1 resection status
(n = 99, 62%) reached significantly higher LRC/OAS
rates than patients with macroscopic loco-regional dis-
ease (n = 61, including 44 patients treated with primary
IMRT, and operated patients with residual (n = 2) or rap-
idly progressive disease in the interval between surgery
and planned postoperative IMRT (n = 15)), p< 0.0001.
Disease control rates in the definitive IMRT subgroup
(n = 44) and in postoperative IMRT patients presenting
with postoperative macroscopic disease (n = 17) were
comparably poor, Table 3.
Ten of the 17 patients who presented with postopera-
tive macroscopic disease had nodal disease only; 6 of
these 10 died from disease, 3 were alive with no signs of
disease when last seen and one patient was alive with
disease. The remaining 7 patients presenting with local
+/− nodal disease all died from disease.
Seven patients were diagnosed with isolated distant
metastasis only, 1–26 months (mean 10) after comple-
tion of IMRT (4% of the cohort: 3 with macroscopic
loco-regional tumor treated with IMRT, 4 with R0-1 sur-
gery prior to IMRT).
Impact of treatment for initial diagnosis versus salvage
treatment
Patients referred for IMRT in the primary (n = 122) ver-
sus salvage treatment of recurrent situation (i.e. loco-
regional OCC recurrence after surgery alone, n = 38,
diagnosed 3–144 months (mean 30) after initial surgery
only), showed comparable LRC and OAS Kaplan Meier
survival curves, when analyzed according to the criterion
‘IMRT for R0-1’ versus ‘IMRT for macroscopic disease’,
Figures 1 and 2, Table 2.
The small sample of patients with disease recurrence
referred for salvage IMRT of macroscopic disease
(n = 10/38) showed very poor outcome (LRC in 1/10, 8/
10 died, 1/10 alive with disease).
Eight of 38 patients were referred for local and nodal re-
currence (rT1-4 rN+), 19 for local recurrence (rT1-4 N+/−
(initially N0)) and 11 for nodal recurrence only (rT0 rN+).
Outcome results and comparison with the non-IMRT lit-
erature of patients treated for recurrent OCC after initial
surgery only are shown in Table 4 [8–11].
Eighteen of the 38 (47%) patients with recurrence after
surgery could undergo R0-1 salvage surgery (Figure 1
and 2, right). This subgroup showed comparable out-
come as patients with R0-1 surgery followed by IMRT at
initial diagnosis (n = 81, Figure 1 and 2, left).
Impact of other parameters
Operated T1 patients attained 100% LRC at 4 years
(n = 17), while operated stage T2-4 patients reached ap-
proximately 70–80% LRC and definitively irradiated
T1-4 patients 30–40% LRC (n cT1 = 1). WHO perform-
ance status showed to be a significant outcome predictor
in the small recurrence subgroup (n = 38, p< 0.005),
while no significant difference was found for the larger
subgroup referred for initial disease (p = 0.06). The dif-
ference in the performance status between operated and
definitively irradiated patients (PS 1–2 17% vs 38%) was
not found to translate in significantly different LRC or
OAS. Systemic therapy (none versus any) and different
systemic treatment schedules (cisplatin or cetuximab,
number of cycles, concomitant +/− induction) did not
show significant outcome differences between the small
subgroups.
The impact of the tumor site was assessed according
to the sites as listed in Table 1. No differences were seen
between the small subgroups when analyzed for the en-
tire group as well as for patients treated with IMRT for
Table 3 Outcome in 160 OCC IMRT patients, analyzed
according to +/− macroscopic disease prior to IMRT
parameters n (%) 4-y LRC 4-y DMFS 4-y OAS
postop IMRT (R0-1) 99 (62) 80% 86% 79%
postop IMRT, macroscopic
disease present
17 (11)) 35% 60% 30%
primary IMRT 44 (27) 37% 86% 37%
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R0-1 versus macroscopic disease. Gender and age also
demonstrated no impact on outcome.
Grade 3/4 late term treatment effects
Treatment tolerance following IMRT with high boost
doses of 60–65 Gy (n = 22), 66 Gy (n = 68), 68 Gy (n = 3),
69.6 Gy or 70 Gy (n = 66) or even 74 Gy (n = 1) was high,
considering that additional systemic therapy was deliv-
ered in 72% of the population. One patient developed a
grade 2–3 RON of the mandible after IMRT, which was
successfully treated by limited surgery (partial decortica-
tion) after 7 months of conservative treatment. One pa-
tient developed a RON following insertion of dental
implants. Two patients remained gastric feeding tube
dependent (one of them after extensive floor of mouth
tumor surgery). There were no patients with persisting
relevant dysphagia or severe grade 3/4 xerostomia. Four
patients developed sub-acute mucosal ulcers grade 4 in
the area of former primary tumor and IMRT boost dose,
which healed after several months (3, 5, 7, and 11 months
after the completion of IMRT).
Discussion
The purpose of the current study was to evaluate the
loco-regional disease control and overall survival in our
large OCC patient cohort treated with IMRT with a longer
follow up than other contemporary published series. The
first 57 previously analyzed OCC patients treated with
IMRT at our institution [5] (see also Table 4) have been
updated and are included in this recent evaluation. The
main limitation of this study is its retrospective character,
and the therefore (expectedly) unbalanced subgroups
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Figure 1 LRC following IMRT in 122 patients with initial OCC diagnosis (left) and in 38 patients with salvage treatment of OCC
recurrence following surgery alone (right).
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Figure 2 OAS following IMRT in 122 patients with initial OCC diagnosis (left) and in 38 patients with salvage treatment of OCC
recurrence following surgery alone (right).
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(definitive vs postoperative IMRT, patients referred for
primary disease vs for recurrence, Table 2). The subgroups
are also expectedly unbalanced with respect to the per-
formance status (PS 1–2 38% vs 17% in definitively irra-
diated vs operated patients) and the primary stage (T3-4
in 62% versus only 34% in operated patients).
We found the presence of macroscopic disease to be a
highly predictive unfavourable outcome parameter. Ini-
tial treatment with primary IMRT (without surgery)
resulted in inferior outcome compared to primary sur-
gery followed by IMRT. Primary IMRT in OCC also
achieved inferior control rates compared to primary
IMRT in all other head and neck sites; unfavourable out-
come in patients irradiated for macroscopic tumor
seems characteristic for OCC, contrary to primary IMRT
for pharyngeal squamous cell carcinoma, which trans-
lates to very satisfactory loco-regional control rates of
~80% (+/− simultaneous systemic therapy) [3,4,10]. The
reason for this difference remains unclear.
Our OCC patients receiving definitive radiation in the
analyzed cohort represent an unfavourable selection –
even the 7 patients with early primaries (cT1-2) all had
advanced nodal disease (N2c (n = 6), N2a (n = 1)). Never-
theless, comparable loco-regional disease at other head
and neck sites achieves much higher control rates. Con-
trary to these advanced stages, excellent results can be
reached in cT1N0 and limited cT2N0 by interstitial
brachytherapy [2].
Operated OCC patients with early recurrence develop-
ing in the short interval between surgery und postopera-
tive IMRT certainly also represent an unfavourable
group with very aggressive tumor features – the poten-
tial benefit of a re-operation in such situations remains
speculative. This subgroup showed a similarly poor out-
come comparable to the definitive IMRT subgroup.
As the other published OCC results are also based on
retrospective case series (Table 4 and 5) there is no de-
finitive randomized evidence so far of the value of post-
operative radiation.
Outcome data on OCC treated with IMRT remain
scant. Table 5 shows published outcome results for
IMRT in OCC [3–5,12–16]. To our knowledge, only two
other reports are available on definitive IMRT patients
to date: Sher et al [15] observed LRC/OAS rates of 64%/
63% at 2 years in 12 patients, Daly et al [16] reported on
7 definitive IMRT patients, with corresponding rates of
60%/56% at 3 years, respectively. Our LRC/OAS rates in
44 definitively irradiated patients were ~40% each at
4 years.
A comparison with the literature of our 38 patients re-
ferred for (definitive or postoperative) salvage IMRT for
recurrence after surgery is listed in Table 4 [8–11]: the
comparison is based on non-IMRT literature, as no data
is available regarding radiation of recurrent disease from
the IMRT era. There is, so far, no evidence for superior-
ity of IMRT compared to non-IMRT techniques with re-
spect to OCC disease control [5,13]. Our small sample
of patients with recurrent macroscopic disease referred
for IMRT (n = 10/38) showed very poor outcome (LRC
in 1/10, 8/10 died, Figures 1, 2), as also reported by
Koo et al [9] and Schwartz et al [8]. In summary, these
studies reported OAS of about 25–35% at 5 years follow-
ing salvage surgery (+/−radiation) of loco-regionally re-
current disease initially treated with surgery only, Table 4
[8–11]. The OAS rate following definitive salvage radio-
therapy in those patients was as low as 0- ~ 20%. Our
IMRT results are somewhat better; when analysed
according to the criterion IMRT for ‘R0-1’ versus ‘macro-
scopic disease’, satisfactory OAS of 75% at 5 years were
attained for 18 patients undergoing radical salvage sur-
gery followed by IMRT.
Poor OAS of approximately 20–30% at 2 years after
salvage therapy is also reported for nodal recurrence fol-
lowing initial surgery +/− radiation (+/−chemotherapy)
[17,18].
The IMRT tolerance in OCC patients was high, con-
firming earlier results regarding RON of the mandible
and occurrence and nature of sub-acute mucosal ulcers
in the IMRT boost dose area [6,7,19–21]. However, no
specific investigations (e.g. quantitative measurement of
salivary flow or quality, swallowing studies) have been
performed to assess xerostomia and dysphagia but
Table 4 Salvage treatment for recurrent OCC following initial surgery
Author [ref] Center Year Interval N recurrences
after surgery alone
IMRT OAS rate after salvage therapy
Surgery (+/−RT) RT (+/−CT)
Schwartz et al [8] U of Illinois, Chicago 2000 1956-1992 38 (28%) no ~25% at 5y (n = 27) 0% at 1y (n = 11)
Koo et al [9] Yonsei U, Seoul 2005 1991-2003 36/127 (28%) no ~25% at 5y (n = 13) 0% at 2y (n = 10)
Liu et al [10] U of Taiwan 2007 1995-2003 224 (na) no 34% at 5y (n = 326)∗ 21% at 2y (n = 75)∗
Kokemueller et al [11] U of Hannover 2011 1980-2009 115/341 (37%) no ~25% at 5y (n = na) 10% at 4y (n = na)
own group U hospital of Zurich 2012 2002-2011 38 (na) yes 55% at 5y (n = 28) 30% at 5y (n = 10)
75% at 5y (n = 18)∗∗ 25% at 5y (n = 20)∗∗
∗: outcome of recurrent OCC following surgery alone (n = 224) and surgery + RT/CT (n = 177).
∗∗: results when analyzed according to ‘salvage IMRT for R0-1 situations’ versus ‘salvage IMRT for macroscopic disease’. U: University. na: not available.
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Table 5 Selected publications on disease control rates following postoperative (n> 300) and definitive IMRT (n= 63) in OCC
Author [ref] Center Year Interval N postop IMRT CT T3/4 N>/=2 lll/lV LRC D M FS O A S
Postop Definitive Postop Definitive Postop Definitive
Eisbruch et al [3] U of MI 2004 1997-2002 27 most postop na na na na 59% (3y) na na na na na
Yao et al [4] U of Iowa 2007 2001-05 55 49 (89%) 11% 56% 36% 91% 85% (3y) na 89% (3y) na 68% (3y) na
Studer et al [5]∗ U of Zurich 2007 2002-07 58 28 (48%) 78% 69% 28% 62% 91% (2y) 43% (2y) 95% (2y) 85% (2y) 83% (2y) 30% (2y), n = 30
Gomez et al [12] MSKCC 2009 2000-06 35 35 (100%) 29% 40% 38% 80% 77% (3y) none 85% (3y) na 74% (3y) none
Chen WC et al [13] Chiayi, Taiwan 2009 2002-05 22 22 (100%) na na 7 (32%) 100% 64% (3y) none na na 67% (3y) none
Collan et al [14] U of Helsinki 2011 2001-2007 40 40 (100%) 38% na na na na none na na 75% (3y) none
Sher D et al [15] DFCI 2011 2004-09 42 30 (71%) ~76% 45% 30% 64% 91% (2y) 64% (2y) 94% (2y) 83% (2y) 85% (2y) 63% (2y), n = 12
Daly M et al [16] Stanford UMC 2011 2002-09 37 30 (81%) 68% 54% 46% 57% 53% (3y) 60% (3y) 81% (3y) 71% (3y) 60% (3y) 57% (3y), n = 7
own cohort U of Zurich 2012 2002-2011 160 99 (62%) ∗∗ 72% 40% 77% 68% 84% (4y) 40% (4y) 90% (4y) 85% (4y) 81% (4y) 38% (4y), n = 44
(∗): included in the recent analysis.
(∗∗): included all patients with R0-1 status (excluded 17 operated patients with macroscopic disease after surgery.
U: University Hospital.
MSKCC: Memorial Sloan-Kettering Cancer Center.
DFCI: Dana-Farber Cancer institute.
UMC: University Medical Center.
CT: Chemotherapy.
LRC: loco-regional control.
DMFS: distant metastasis free survival.
OAS: overall survival.
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clinical follow up examinations (as mentioned in ‘meth-
ods’) and routine chart reviews on patients’ complaints
were undertaken. The fact that only 2 patients remained
feeding tube dependent may serve as a surrogate for suf-
ficient swallowing capacity< grade 3 toxicity.
Conclusions
IMRT for postoperative R0-1 situations translated into
a significant superior LRC and OAS compared to the
IMRT cohort treated for macroscopic disease
Patients with recurrent disease (following surgery
alone) showed similar outcome as patients irradiated
for the initial situation, when analyses were performed
according to the criteria ‘IMRT for R0-1’ versus ‘IMRT
for macroscopic disease’
Persistent grade 3/4 late effects following IMRT
(+/- systemic therapy) developed in <2% of our cohort
These updated findings corroborate our earlier recom-
mendation in favour of a multi-modality approach with
surgery followed by postoperative IMRT(-chemotherapy)
in advanced OCC.
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